Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 5/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611607 | 1.00 | ADORA1 (0.54) | ADORA1ADORA3ADORA2AHTR2BSIGMAR1 | |
| SCHEMBL23273892 | 0.87 | ADORA3 (0.44) | ADORA1ADORA3ADORA2AHTR2BSIGMAR1 | |
| SCHEMBL29610954 | 0.86 | PRMT5 (0.47) | ADORA1ADORA3ADORA2AADK | |
| SCHEMBL29611468 | 0.86 | PRMT5 (0.47) | ADORA1ADORA3ADORA2AADK | |
| SCHEMBL24313850 | 0.86 | PRMT5 (0.47) | ADORA1ADORA3ADORA2AADK | |
| SCHEMBL9280202 | 0.85 | METTL3 (0.60) | ADORA1ADORA3ADORA2AADKSLC28A2 | |
| SCHEMBL19583130 | 0.84 | ADORA1 (0.75) | ADORA1ADORA3ADORA2APRKAG1PRKAA1 | |
| SCHEMBL640190 | 0.84 | ADORA1 (0.75) | ADORA1ADORA3ADORA2APRKAG1PRKAA1 | |
| SCHEMBL17825998 | 0.84 | ADORA1 (0.75) | ADORA1ADORA3ADORA2APRKAG1PRKAA1 | |
| SCHEMBL640189 | 0.84 | ADORA1 (0.75) | ADORA1ADORA3ADORA2APRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS INC (US) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051985-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | ADORA1 2456/4885ADORA3 684/4885ADORA2A 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.